PLRX Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2024-04-22 | 2023 | Bernard Coulie, M.D., Ph.D., MBA President, Chief Executive Officer and Director | 610,300 | 0 | 5,069,295 | 335,665 | 51,003 | 11,165,999 |
| 2024-04-22 | 2021 | Mike Ouimette, J.D. General Counsel and Corporate Secretary | 362,693 | 0 | 0 | 174,092 | 1,200 | 805,039 |
| 2024-04-22 | 2022 | Mike Ouimette, J.D. General Counsel and Corporate Secretary | 398,000 | 0 | 1,270,206 | 191,040 | 2,009 | 2,542,248 |
| 2024-04-22 | 2023 | Mike Ouimette, J.D. General Counsel and Corporate Secretary | 425,900 | 0 | 1,351,350 | 170,360 | 9,768 | 3,316,978 |
| 2024-04-22 | 2021 | Hans Hull, J.D. Chief Business Officer | 385,735 | 0 | 0 | 185,153 | 11,600 | 1,653,630 |
| 2024-04-22 | 2022 | Hans Hull, J.D. Chief Business Officer | 407,000 | 0 | 1,642,517 | 211,640 | 13,000 | 3,154,751 |
| 2024-04-22 | 2023 | Hans Hull, J.D. Chief Business Officer | 427,300 | 0 | 1,871,100 | 170,920 | 4,293 | 4,357,277 |
| 2024-04-22 | 2021 | Éric Lefebvre, M.D. Chief Medical Officer | 455,981 | 0 | 0 | 246,230 | 11,600 | 1,974,231 |
| 2024-04-22 | 2022 | Éric Lefebvre, M.D. Chief Medical Officer | 481,100 | 0 | 2,044,000 | 269,416 | 12,971 | 3,903,337 |
| 2024-04-22 | 2023 | Éric Lefebvre, M.D. Chief Medical Officer | 500,300 | 0 | 1,975,050 | 220,131 | 13,980 | 4,687,061 |
| 2024-04-22 | 2021 | Keith Cummings, M.D., MBA Chief Financial Officer | 401,700 | 0 | 0 | 192,816 | 11,600 | 1,883,743 |
| 2024-04-22 | 2022 | Keith Cummings, M.D., MBA Chief Financial Officer | 427,200 | 0 | 1,810,400 | 222,144 | 13,000 | 3,443,354 |
| 2024-04-22 | 2023 | Keith Cummings, M.D., MBA Chief Financial Officer | 452,800 | 0 | 1,871,100 | 217,344 | 14,000 | 4,438,908 |
| 2024-04-22 | 2021 | Bernard Coulie, M.D., Ph.D., MBA President, Chief Executive Officer and Director | 556,200 | 0 | 0 | 321,206 | 42,172 | 5,221,353 |
| 2024-04-22 | 2022 | Bernard Coulie, M.D., Ph.D., MBA President, Chief Executive Officer and Director | 586,800 | 0 | 6,424,000 | 440,000 | 32,815 | 10,927,715 |
| 2023-04-26 | 2021 | Mike Ouimette, J.D. General Counsel and Corporate Secretary | 362,693 | 0 | 0 | 174,092 | 1,200 | 805,039 |
| 2023-04-26 | 2022 | Bernard Coulie, M.D., Ph.D. President, Chief Executive Officer and Director | 586,800 | 0 | 6,424,000 | 440,000 | 32,815 | 10,927,715 |
| 2023-04-26 | 2021 | Bernard Coulie, M.D., Ph.D. President, Chief Executive Officer and Director | 556,200 | 0 | 0 | 321,206 | 42,172 | 5,221,353 |
| 2023-04-26 | 2022 | Keith Cummings, M.D., MBA Chief Financial Officer | 427,200 | 0 | 1,810,400 | 222,144 | 13,000 | 3,443,354 |
| 2023-04-26 | 2021 | Keith Cummings, M.D., MBA Chief Financial Officer | 401,700 | 0 | 0 | 192,816 | 11,600 | 1,883,743 |
| 2023-04-26 | 2022 | Hans Hull, J.D. Chief Business Officer | 407,000 | 0 | 1,642,517 | 211,640 | 13,000 | 3,154,751 |
| 2023-04-26 | 2021 | Hans Hull, J.D. Chief Business Officer | 385,735 | 0 | 0 | 185,153 | 11,600 | 1,653,630 |
| 2023-04-26 | 2022 | Éric Lefebvre, M.D. Chief Medical Officer | 481,100 | 0 | 2,044,000 | 269,416 | 12,971 | 3,903,337 |
| 2023-04-26 | 2021 | Éric Lefebvre, M.D. Chief Medical Officer | 455,981 | 0 | 0 | 246,230 | 11,600 | 1,974,231 |
| 2023-04-26 | 2022 | Mike Ouimette, J.D. General Counsel and Corporate Secretary | 398,000 | 0 | 1,270,206 | 191,040 | 2,009 | 2,542,248 |
| 2022-04-29 | 2021 | Bernard Coulie, M.D., Ph.D. President, Chief Executive Officer and Director | 556,200 | 0 | 0 | 321,206 | 11,600 | 5,190,781 |
| 2022-04-29 | 2021 | Barbara Howes, MBA Former Chief Human Resources Officer | 254,521 | 0 | 0 | 0 | 10,090 | 995,913 |
| 2022-04-29 | 2021 | Mike Ouimette, J.D. General Counsel and Corporate Secretary | 362,693 | 0 | 0 | 174,092 | 1,200 | 805,039 |
| 2022-04-29 | 2020 | Éric Lefebvre, M.D. Chief Medical Officer | 425,462 | 0 | 0 | 209,176 | 11,400 | 874,671 |
| 2022-04-29 | 2021 | Éric Lefebvre, M.D. Chief Medical Officer | 455,981 | 0 | 0 | 246,230 | 11,600 | 1,974,231 |
| 2022-04-29 | 2019 | Hans Hull, J.D. Chief Business Officer | 355,137 | 75,000 | 0 | 136,369 | 11,200 | 846,266 |
| 2022-04-29 | 2020 | Hans Hull, J.D. Chief Business Officer | 372,491 | 0 | 0 | 176,951 | 11,400 | 839,867 |
| 2022-04-29 | 2021 | Hans Hull, J.D. Chief Business Officer | 385,735 | 0 | 0 | 185,153 | 11,600 | 1,653,630 |
| 2022-04-29 | 2021 | Keith Cummings, M.D., MBA Chief Financial Officer | 401,700 | 0 | 0 | 192,816 | 11,600 | 1,883,743 |
| 2022-04-29 | 2019 | Bernard Coulie, M.D., Ph.D. President, Chief Executive Officer and Director | 428,108 | 2,000 | 0 | 219,193 | 49,905 | 2,372,486 |
| 2022-04-29 | 2020 | Bernard Coulie, M.D., Ph.D. President, Chief Executive Officer and Director | 499,037 | 0 | 0 | 351,000 | 45,229 | 2,391,822 |
| 2021-04-30 | 2019 | Bernard J. Coulie, M.D., Ph.D. Chief Executive Officer | 428,108 | 2,000 | 0 | 219,193 | 49,905 | 2,372,486 |
| 2021-04-30 | 2019 | Hans Hull, J.D. Chief Business Officer | 355,137 | 75,000 | 0 | 136,369 | 11,200 | 846,266 |
| 2021-04-30 | 2020 | Hans Hull, J.D. Chief Business Officer | 372,491 | 0 | 0 | 176,951 | 11,400 | 839,867 |
| 2021-04-30 | 2020 | Éric Lefebvre, M.D. Chief Medical Officer | 425,462 | 0 | 0 | 209,176 | 11,400 | 874,670 |
| 2021-04-30 | 2020 | Bernard J. Coulie, M.D., Ph.D. Chief Executive Officer | 499,037 | 0 | 0 | 351,000 | 45,229 | 2,391,822 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
